The Hardest Thing About Building Something Real Is the Waiting.

If you are building a company right now, or thinking about it, I want to talk to you about something that does not get discussed enough.

Not the funding rounds. Not the go-to-market strategy. Not the pitch decks or the product launches or the milestone announcements that everyone celebrates on LinkedIn.

I want to talk about the years in between. The years when nothing is happening, at least not in any way the outside world can see. The years when the work is invisible and the results are nowhere and the temptation to take a shortcut becomes very loud indeed.

Because that is the part of building Numin that changed me most. And I think it is the part that separates the companies that stand for something from the ones that simply sell something.

The Decision Nobody Sees

When we set out to build Numin, we made a choice early on that shaped everything that came after it. We decided that we would not bring a product to market until we had clinical proof that it worked. Not borrowed evidence from studies on individual ingredients. Not anecdotal feedback from early users. A proper, randomised, double-blind, placebo-controlled clinical trial on the finished formula itself.

In the supplement industry, that decision is unusual. Most companies do not make it. The barrier to launching a supplement is remarkably low. You can source ingredients, blend a formula, design some packaging, and be on shelves within months. No clinical trial required. No proof of efficacy required. Just a label, some claims that stay just within the regulatory lines, and a marketing budget.

We could have done that. We chose not to.

What followed was years of work that produced nothing you could point to. No product on shelves. No revenue. No announcements. Just the slow, painstaking process of designing a study, obtaining ethics approvals, recruiting participants, running the trial, collecting the data, analysing the results, writing the manuscript, submitting to peer review, responding to reviewer feedback, and waiting.

“The years when nothing is happening are often the years when everything important is being built.”

What Waiting Actually Feels Like

I want to be honest about what that period was like, because I think founders and builders deserve honesty more than inspiration.

Waiting, when you are waiting for something that matters to you deeply, is not passive. It is one of the most active and demanding states I have ever experienced. You are holding belief in one hand and uncertainty in the other, every single day, with no guarantee that the results will vindicate the choice you made.

We did not know how the trial would come out. That is the nature of real science. You design the best study you can, you run it with rigour and integrity, and then the data tells you what it tells you. There is no predetermined outcome. There is no guarantee.

I remember moments of genuine doubt. Not about the science behind the ingredients, which I believed in deeply and had spent years researching. But about whether the finished formula, in the specific doses and combinations we had chosen, would produce effects that were measurable and meaningful. Whether the study would be powered sufficiently to detect them. Whether the environment we had chosen, competitive gaming over 13 hours, would be the right stress test.

You sit with those questions for a long time. And you keep working anyway.

Why We Kept Going

There is a version of this story where we got impatient. Where the pressure of time and money and market opportunity became louder than the commitment to doing it properly. That version of the story exists for a lot of companies. It is how you end up with an industry full of products that make promises they have never been asked to keep.

We kept going because of what we believed Numin could be, not just as a product, but as a proof of concept for a different way of building in this space.

The supplement industry has a trust problem. Consumers are increasingly sophisticated. They read labels. They question claims. They have been burned by products that promised results and delivered nothing. And they are right to be sceptical. Most of what is on the market deserves scepticism.

We wanted Numin to be the answer to that scepticism. Not the kind of answer that says trust us, but the kind that says here is the evidence, read it for yourself, and decide.

That meant doing the work nobody sees. And it meant waiting for it to be finished before we said a word.

What the Results Gave Us

When the data came back, and when it showed what it showed, the feeling was not triumphant in the way I had imagined during all those months of waiting. It was quieter than that. More like relief. Like the foundation had held.

The Numin group showed a 4.5% increase in win rates over the course of the study while the placebo group saw theirs fall. They maintained consistent decision-making behaviours across a 13-hour session while the placebo group deteriorated. Their mouse input patterns showed more deliberate, attentive behaviour. The biology did what we believed it would do.

And then we went through peer review. Which is its own kind of waiting, its own kind of crucible. Independent scientific experts with no stake in our success scrutinised every aspect of the study design, the methodology, the statistical analysis, the conclusions. They pushed back. We responded. We revised. We resubmitted.

When Frontiers in Nutrition accepted the paper, that was the moment. Not because of what it meant for marketing or for credibility, though it meant a great deal for both. But because it meant the work had been independently validated by people who had every reason to reject it and chose not to.

“We wanted Numin to be the answer to scepticism. Not the kind that says trust us, but the kind that says here is the evidence, read it for yourself.”

What This Means for You

If you are a founder or a builder reading this, I am not going to pretend that our path is the only valid one or that every company should take years to go to market. Context matters. Industry matters. The nature of your product matters.

But I do want to say this: the shortcuts are always visible in the end. Not immediately, and sometimes not for years. But eventually, what you chose not to do catches up with what you built. The companies that last, the ones that build genuine trust with their customers, are almost always the ones that made a hard choice early and held to it when holding was costly.

For us, that choice was clinical validation. It was the decision to treat our customers as people who deserved proof, not promises. It was the choice to wait until we had something real to say before we said anything.

Every sachet of Numin that exists today is the product of that choice. The years of invisible work. The peer-reviewed science. The refusal to launch before we were ready.

When you pick up Numin, you are not buying a hope or a hunch. You are buying the result of a commitment that was made long before there was anything to sell. A commitment to doing it properly, even when properly was slow, expensive, and deeply uncertain.

I think that is worth something. I think, if you care about what you put in your body and what you invest your trust in, it is worth quite a lot.

The Work Continues

We are not done. A single published pilot study is a foundation, not a finish line. We are committed to continuing the research, expanding the evidence base, and holding ourselves to the same standard in everything that comes next.

Because that is what it means to build something real. Not one good decision made once, but the same hard choice made again and again, every time the shortcut presents itself.

We made it before. We will keep making it.

And if you are in the middle of your own version of the wait right now, building something you believe in and wondering whether the harder path is worth it, I want you to know: it is. The foundation you are laying in the invisible years is the thing that will hold everything else up.

Keep going.